Cubosomes a drug delivery system ❖Introduction : • Cubosomes are the square and rounded particles with internal cubic lattices visible. • Cubosomes are self-assembled nanostructured particles formed by aqueous lipid and surfactant systems. • Cubosomes are thermodynamically stable; they have a structure like “honeycombed”. 2 ❖Defination : • Cubosomes are nanoparticles but instead of the solid particles usually encountered, cubosomes are self-assembled liquid crystalline particles with a solid-like rheology that provides unique properties of practical interest. Fig. Cubosomes with different drug loading modalities 3 ❖Advantages of Cubosomes • 1.High drug payloads due to high internal surface area and cubic crystalline structures. • 2.Relatively simple method of preparation. • 3.Biodegradability of lipids. • 4.Capability of encapsulating hydrophilic, hydrophobic and amphiphilic substances. 4 • 5. Targeted release and controlled release of bioactive agents. • 6. While most liquid crystalline systems transform into micelles at higher levels of dilution, cubosomes remain stable almost at any dilution level because of the relative insolubility of cubic phase forming lipid in water. So, cubosomes can easily be incorporated into product formulations. • 7. The cubic phases of cubosomes can form particulate dispersions that are colloidally and thermodynamically stable for longer time. 5 ❖Disadvantages of Cubosomes • Large scale production is sometimes difficult because of high viscosity. 6 ꙮꙮꙮ Manufacture of Cubosomesꙮꙮꙮ Cubosomes can be manufactured by two distinct methods: 1. Top down technique 2. Bottom up technique ❖ Liquid Cubosomes Precursors :- (The Hydrotrop Dilution Process) ❖ Powder Cubosomes Precursors

1. CUBOSOMES-A DRUG
DELIVERY SYSTEM
Shrikant R. Divekar
M.Pharm 1 Year
(Pharmaceutics)
1
Guided By :- Prof. Shitole M.
Prof. Kakde S.
Prof. Khade P.H.
P.D.E.A Shankarrao Ursal Collage of
Pharmaceutical Sciences &
Research Center Kharadi,Pune - 14

2. ❖Introduction :-
• Cubosomes are the square and rounded particles with internal cubic
lattices visible.
• Cubosomes are self-assembled nanostructured particles formed by
aqueous lipid and surfactant systems.
• Cubosomes are thermodynamically
stable; they have a structure like
“honeycombed”.
2

3. ❖Defination :-
• Cubosomes are nanoparticles but instead of the solid particles usually
encountered, cubosomes are self-assembled liquid crystalline
particles with a solid-like rheology that provides unique properties of
practical interest.
Fig. Cubosomes with different drug loading modalities
3

4. ❖Advantages of Cubosomes
• 1.High drug payloads due to high internal surface area and cubic
crystalline structures.
• 2.Relatively simple method of preparation.
• 3.Biodegradability of lipids.
• 4.Capability of encapsulating hydrophilic, hydrophobic and
amphiphilic substances.
4

5. • 5. Targeted release and controlled release of bioactive agents.
• 6. While most liquid crystalline systems transform into micelles at
higher levels of dilution, cubosomes remain stable almost at any
dilution level because of the relative insolubility of cubic phase
forming lipid in water. So, cubosomes can easily be incorporated into
product formulations.
• 7. The cubic phases of cubosomes can form particulate dispersions
that are colloidally and thermodynamically stable for longer time.
5

6. ❖Disadvantages of Cubosomes
• Large scale production is sometimes difficult because of high viscosity.
6

7. ꙮꙮꙮ Manufacture of Cubosomes ꙮꙮꙮ
Cubosomes can be manufactured by two distinct methods:
1. Top down technique
2. Bottom up technique
❖ Liquid Cubosomes Precursors :- (The Hydrotrop Dilution Process)
❖ Powder Cubosomes Precursors
7

8. 8

9. 9

10. 10

11. 11

12. 12

13. 13

14. 14

15. METHODS FOR CHARACTERIZATION AND
EVALUATION OF CUBOSOMES
• 1) Gel permeation chromatography or ultra filtration techniques & UV
spectrophotometer or HPLC analysis
• 2) Photon correlation spectroscopy
• 3) X-ray scattering
• 4) Transmission electron microscopy
• 5) Pressure Ultrafiltration Method
• 6) Stability studies
• 7) Visual inspection
• 8) Light microscopy
• 9) Entrapment efficiency
• 10) Viscosity
• 11) In-vitro drug release
15

16. 1) Gel permeation chromatography or ultra filtration
techniques & UV spectrophotometer or HPLC analysis
• Entrapment efficiency and drug loading of cubosomes can be
determined using gel permeation chromatography or ultra filtration
techniques.
• In the later technique, unentrapped drug concentration is
determined, which is subtracted from the total drug added.
• The amount of drug is analyzed by using UV spectrophotometer or
HPLC analysis.
16

17. 2) Photon correlation spectroscopy
• Particle size distributions of cubosomes are mainly determined by
dynamic laser light scattering using Zeta sizer (Photon correlation
spectroscopy).
• The sample diluted with a suitable solvent is adjusted to light
scattering intensity of about 300 Hz and measured at 25°C in
triplicate.
• The data can be collected and generally shown by using average
volume weight size.
• The zeta potential and polydispersity index can also be recorded.
17

18. 3) X-ray scattering
• Small angle X-ray scattering (SAXS) can be used to identify the spatial
arrangements of different groups in the sample.
• The diffraction patterns obtained used to identify the dominant
internal nanostructure of the sample.
18

19. 4) Transmission electron microscopy
• Transmission electron microscopy can be used to view the shape of
the cubosomes
• SEM analysis may not be performed on cubosomes or some vesicular
systems since the integrity and robustness of the formulation may be
lost during the procedure while exposing to electron array.
19

20. 5) Pressure Ultrafiltration Method
• Drug release measurement of cubosomes can be done by pressure
ultrafiltration method.
• It is based closely on that proposed by Magenheim et al. using an
Amicon pressure ultrafiltration cell fitted with a Millipore membrane
at ambient temperature (22±2) °C.
20

21. 6) Stability studies
• The physical stability can be studied by investigation of organoleptic
and morphological aspects(properties) as a function of time.
• Particle size distribution and drug content can be assessed at different
time intervals can also be used to evaluate the possible variations by
time.
21

22. 7) Visual inspection
• About 1 week after preparation, the dispersions were visually
assessed for optical appearance
(e.g., colour, turbidity, homogeneity, presence of macroscopic particles).
22

23. 8) Light microscopy
• Samples of the prepared cubosomes were suitably diluted with
deionized water and examined using an optical microscope (Lecia
DMRXP) to determine its structure and its particle size.
23

24. 9) Entrapment efficiency
• The amount of free drug in the dispersion was then analyzed
spectrophotometrically at λmax 250 nm, this was then subtracted
from the total amount of drug initially added.
EE % of cubosomes = [(Ct – Cf)/Ct] x 100
• (Cf) namely that not encapsulated in cubosomes.
• This was then subtracted from the total drug concentration (Ct) in the
formulation to give the amount of drug that was successfully
entrapped inside the cubosomes.
24

25. 10) Viscosity
• The viscosity of the prepared formulations was determined at
different angular velocities at 25o C using a rotary viscometer
(Brookfield).
• The rotation speed was 20 rpm, with spin # 18.
• The average of three readings was used to calculate the viscosity.
25

26. 11) In-vitro drug release
• Samples of ALA cubosome dispersions for release studies Sample was
placed in a disc and covered by a membrane then placed at the bottom of
the dissolution vessel using dissolution tester type II
• (The membrane was used to retain the formula inside the disc.
• The apparatus was equilibrated to 32 ± 0.5 °C and the stirrer paddle speed
was set at 50 rpm.
• Sample are withdrawn at appropriate time intervals (0.5, 1, 2, 3, 4, 5 and 6
hrs) and filtered through a syringe filter having a pore size of 0.1 μm then
analyzed spectrophotometrically at wavelength of 250 nm (according to
the method of drug assay).
• The amount of drug released was calculated from the standard curve.
26

27. ꙮ CUBOSOME APPLICATIONS ꙮ
• 1) Melanoma (cancer) therapy
• Recently few anticancer drugs have been successfully encapsulated in
cubosomes. The unique structure of this promising nanocarrier suggests its
application in melanoma therapy.
• The tumour microenvironment is highly heterogeneous in composition with
as much as half of its volume occupied by noncancerous cells and dense
extracellular matrix. Furthermore, the hyperpermeable nature of the
tumourvas culature, while being ideal for allowing nanoparticles to enter into
tumour tissue, also allows fluid to leak from the vessel into the tumour
microenvironment, thereby causing extra ordinarily high interstitial pressure
throughout the tumour interior.
• The interstitial pressure tends to increase with increasing tumour volume and
remain lower in the outermost areas of the tumour.
27

28. • 2) Oral drug delivery
• Cubosomes address the varied challenges in oral delivery of numerous
promising compounds including poor aqueous solubility, poor absorption, and
large molecular size.
• In an alternative application large proteins have been encapsulated for local
activity in the gastrointestinal tract.
• Liquid crystalline nanoparticles technology carriers can be combined with
controlled release and targeting functionalities.
• The particles are designed to form in situ in a controlled rate, which enables
an effective in vivo distribution of the drug.
• Cubosomes technology carriers can also be released at different absorption
sites, for example in the upper or lower intestine, which is important for the
drugs that have narrow regional absorption window.
28

29. • 3) Intravenous drug delivery systems
• Lipid nanoparticles comprising interior liquid crystal structures of curved lipid
membranes are used to solubilize encapsulate and deliver medications to
disease areas within the body.
• While emulsions and liposomes have found use as intravenous carriers in
drug products, liquid crystal nanoparticle structures increased payloads of
peptides, proteins and many insoluble small molecules, and are ideal carriers
for injection or infusion of many actives.
29

30. • 4) Topical drug delivery systems
• Cubic phases are more bioadhesive in nature
• So that they can conveniently use in topical and mucosal depositions and
delivery of different drugs.
• Topical delivery systems are based properties of liquid crystal (LC) and liquid
crystal nanoparticle (LCNP) technologies.
• Topical drug delivery systems are used in controlled and effective drug
delivery to mucosal surfaces (buccal, ophthalmic, vaginal and others).
• This system forms a thin surface film at mucosal surfaces consisting of a liquid
crystal matrix which nanostructure can be controlled for achieving an optimal
delivery profile and provides good temporary protection of sore and sensitive
skin
30

31. • 5) Drug delivery vehicle
• Drug delivery vehicle is a common application for such new materials.
• The rapid expansion of the life-sciences industry is expected to drive
previously “exotic” delivery vehicles and ingredients into broader
marketplaces, such as personal care and consumer products.
• Consequently, self-assembled surfactant phases have been extensively
examined for compatibility with numerous medical active ingredients and
their applications.
• The number of research in association with cosmetic companies like L’Oreal
and Nivea are trying for the use of cubosome particles as oil-in-water
emulsion stabilizers and pollutant absorbents in cosmetics.
31

32. • 6) As sustained release behavior
• Even more recent patent activity by points to cubosome use in personal care
product areas as varied as skin care, hair care, cosmetics, and antiperspirants.
• The cubic phase has been shown to provide a vehicle for several in vivo
delivery routes, including depot, transdermal, mucoadhesion and ophthalmic.
• It increases the penetration of macro molecules.
• A wide variety of drugs with different physicochemical properties have been
incorporated in cubosomes, and their sustained release behavior was also
studied.
• Sustained behavior of cubosomes was because of cubosome remnant
particles. Monoglyceride based cubosome dispersion can be proposed for
topical use, such as for perctuneous or mucosal applications.
32

33. • 7) In treatment of viral diseases
• Because of the microbicidal (killing microbes) properties of monoglycerieds,
could be used to design intravaginal treatment of sexually transmitted
diseases caused by viruses (e.g. HSV, HIV)
• 8) In topical and mucosal depositions
• Cubic phases are more bioadhesive in nature, so that they can conveniently
used in topical and mucosal depositions and delivery of different drugs.
33

34. Current application
• 1. An application area under current development by L‟Oreal is the
use of cubosome particles as oil-in-water emulsion stabilizers and
pollutant absorbents in cosmetics.
• 2. In melanoma therapy (cancer).
34

35. References
• CUBOSOMES-A DRUG DELIVERY SYSTEM Komal Tilekar*, Prashant
Khade, Sujit Kakade, Sachin Kotwal and RavindraPatil PDEA’S,
Shankarrao Ursal College of Pharmaceutical Sciences And Research
Centre, Kharadi, Pune-14, Maharashtra, India.
• https://www.slideshare.net/MarwaAbdElKader/cubosomes
35